Атиповий гемолітико-уремічний синдром очима акушера (Огляд літератури)
DOI:
https://doi.org/10.15574/HW.2019.138.91Ключові слова:
вагітність, акушерський атиповий гемолітико-уремічний синдром, екулізумабАнотація
У статті представлено огляд вітчизняної та зарубіжної літератури щодо атипового гемолітико-уремічного синдрому. Представлено також сучасну термінологію, класифікацію, розглянуто питання щодо причин та патогенезу цієї патології. Наведено думку фахівців акушерсько-гінекологічних спільнот світу з питань його клініки, діагностики та лікування.
Посилання
Kirsanova TV, Merkusheva LI, Kozlovskaya NL, Fedorova TA i soavt. 2013. Atipichnyiy gemolitiko-uremicheskiy sindrom pri beremennosti: osobennosti techeniya, slozhnosti diagnostiki, podhodyi k terapii. Akusherstvo i ginekologiya 6: 70–75.
Kozlov LV. 2002. Issledovanie funktsionalnoy aktivnosti komponentov i faktorov sistemy komplementa cheloveka. Voprosyi meditsinskoy himii 48 (6): 624–631.
Kozlovskaya NL, Merkusheva LI, Kirsanova TV, Runihina NK. 2012. Osobennosti techeniya i ishoda atipichnogo gemolitiko-uremicheskogo sindroma pri beremennosti. Klinicheskaya nefrologiya 3: 44–49.
Kozlovskaya NL, Korotchaeva YuV. 2016. Atipichnyiy gemolitiko-uremicheskiy sindrom v akusherskoy praktike: pervyiy rossiyskiy opyit diagnostiki i lecheniya. Rossiyskiy vestnik akushera-ginekologa 6: 95–104.
Korotchaeva YuV, Kozlovskaya NL, Bondarenko TV, Veselov GA. 2015. «Akusherskiy» atipichnyiy gemolitiko-uremicheskiy sindrom: trudnyiy diagnoz? Arhiv akusherstva i ginekologii im. V.F. Snegireva. 2: 36–41.
Lora Sh, Fremyu-Bachi V. 2012. Atipichnyiy gemolitiko-uremicheskiy sindrom. Nefrologiya 16 (2): 16-46.
Prokopenko EI, Lihvantsev VV, Vatazin AV, Lopatin AF i soavt. 2016. Atipichnyiy gemolitiko-uremicheskiy sindrom, assotsiirovannyiy s beremennostyu: zhiznespasayuschaya terapiya ekulizumabom. Klinicheskaya nefrologiya 3:63–68.
Pyiregov AV, Fedorova TA, Korolev AYu, Grischuk KI. 2016. Atipichnyiy gemolitiko-uremicheskiy sindrom u patsientki s menometrorragiey (klinicheskoe nablyudenie). Vestnik anesteziologii i reanimatologii 13 (3):63–70.
Smirnov AV, Karunnaya AV, Dobronravov VA. 2017. Nefrologicheskie aspektyi komplement-oposredovannoy tromboticheskoy mikroangiopatii. Terapevticheskiy arhiv 89 (6): 34–40.
Ulitkina ON, Filippovskaya ZhS, Prokopenko EI, Ovezov AM i soavt. 2015. Uspeshnoe lechenie atipichnogo gemolitiko-uremicheskogo sindroma u rodilnitsyi. Obschaya reanimatologiya 11(6): 61–68.
Bao L, Quigg RJ. 2007. Complement in lupus nephritis: the good, the bad, and the unknown. Semin Nephrol. 27 (1): 69–80. https://doi.org/10.1016/j.semnephrol.2006.09.009; PMid:17336690
Besbas N, Karpman D, Landau D et al. 2006. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int. 70: 423–431. https://doi.org/10.1038/sj.ki.5001581; PMid:16775594
Burwick RM, Feinberg BB. 2013. Eculizumab for the treatment of preeclampsia/HELLP syndrome. Placenta 34: 201–203. https://doi.org/10.1016/j.placenta.2012.11.014; PMid:23228435
Campistol JM, Arias M, Ariceta G, Blasco M et al. 2015. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia 35 (5): 421–447. https://doi.org/10.1016/j.nefro.2015.07.005; PMid:26456110
Caprioli J, Noris M, Brioschi S et al. 2006. International Registry of Recurrent and Familial HUS/TTP. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 108: 1267–79. https://doi.org/10.1182/blood-2005-10-007252; PMid:16621965 PMCid:PMC1895874
Cataland SR, Holers VM, Geyer S, Yang S et al. 2014. Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP. Blood.123 (24):3733–8. https://doi.org/10.1182/blood-2013-12-547067; PMid:24695849
Cheong HI et al. 2016. Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea. Journal of Korean medical science 31 (10): 1516–28. https://doi.org/10.3346/jkms.2016.31.10.1516; PMid:27550478 PMCid:PMC4999392
Constantinescu AR, Bitzan M, Weiss LS et al. 2004. Non-enteropathic hemolytic uremic syndrome: causes and short-term course. Am. J. Kidney Dis. 43: 976–982. https://doi.org/10.1053/j.ajkd.2004.02.010; PMid:15168377
Coppo P, Bussel A, Charrier S et al. 2003. High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome. Medicine (Baltimore) 82: 27–38. https://doi.org/10.1097/00005792-200301000-00003; PMid:12544708
Demyanova KA, Kozlovskaya NL, Bobrova LA, Kozlov LV et al. 2017. Complement System Abnormalities in Patients with Atypical Hemolytic Uremic Syndrome and Catastrophic Antiphospholipid Syndrome. Annals of the Russian Academy of Medical Sciences 72 (1): 42–52. https://doi.org/10.15690/vramn769; PMid:29308852
Fakhouri F, Roumenina L, Provot F et al. 2010. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J. Am. Soc. Nephrol. 21 (5): 859–867. https://doi.org/10.1681/ASN.2009070706; PMid:20203157 PMCid:PMC2865741
Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaime F et al. 2013. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin. J. Am. Soc. Nephrol. 8 (4): 554–562. https://doi.org/10.2215/CJN.04760512; PMid:23307876 PMCid:PMC3613948
Hofer J, Rosales A, Fischer C, Giner T. 2014. Extra-renal manifestations of complement-mediated thrombotic microangiopathiess. Front Pediatr. 2: 97. https://doi.org/10.3389/fped.2014.00097; PMid:25250305 PMCid:PMC4157546
Jokiranta TS. 2017. HUS and atypical HUS. Blood. 129 (21): 2847–56. https://doi.org/10.1182/blood-2016-11-709865; PMid:28416508 PMCid:PMC5445567
Kavanagh D, Richards A, Fremeaux-Bacchi V et al. 2007. Screening for complement system abnormalities in patients with atypical hemolytic uremic syndrome. Clin. J. Am. Soc. Nephrol. 2 (3): 591–596. https://doi.org/10.2215/CJN.03270906; PMid:17699467
Kavanagh D, Goodship TH. 2011. Atypical hemolytic uremic syndrome, genetic basis and clinical manifesatations. Hematology Am. Soc. Hemat. Educ. Program.:15–17. https://doi.org/10.1182/asheducation-2011.1.15; PMid:22160007
Kavanagh D, Goodship TH. 2010. Atypical hemolytic uremic syndrome. Curr. Opin. Hematol. 17 (5): 432–438. https://doi.org/10.1097/MOH.0b013e32833cae86; PMid:20613506
Keating G.M. 2013. Eculizumab: a review of its use in atypical haemolytic uraemic syndrome. Drugs. 73: 2053–66. https://doi.org/10.1007/s40265-013-0147-7; PMid:24249647
Kourouklaris A, Ioannou K, Athanasiou L. 2014. Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report. J. Med. Case. Rep. 8: 307. https://doi.org/10.1186/1752-1947-8-307; PMid:25219386 PMCid:PMC4170201
Lemaire M, Frémeaux-Bacchi V, Schaefer F, Choi M et al. 2013. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat. Genet. 45: 531–536. https://doi.org/10.1038/ng.2590; PMid:23542698 PMCid:PMC3719402
Licht C, Weyersberg A, Heinen S et al. 2005. Successful plasma therapy for atypicalhemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. Am. J. Kidney. Dis. 45: 415–21. https://doi.org/10.1053/j.ajkd.2004.10.018; PMid:15685522
Loirat C, Fakhouri F, Ariceta G, Besbas N et al. 2016. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr. Nephrol. 31 (2): 15–39. https://doi.org/10.1007/s00467-015-3076-8; PMid:25859752
Mackaness CA, Fleszler F. 2014. Eculizumab in the successful treatment of postpartum hemolytic uremic syndrome – a case report. Poster presented at the national kidney foundation, spring clinical meetings, Las Vegas: 22–24.
McMinn JR, George JN. 2001. Evaluation of women with clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome during pregnancy. CUn. Apker. 16: 202–209. https://doi.org/10.1002/jca.10005; PMid:11835417
Melis JP, Strumane K, Ruuls SR et al. 2015. Complement in therapy and disease: regulating the complement system with antibody-based therapeutics. Mol Immunol. 67:117–130. https://doi.org/10.1016/j.molimm.2015.01.028; PMid:25697848
Meri S. 2013. Complement activation in diseases presenting with thrombotic microangiopathy. Eur. J. Intern. Med. 24 (6): 496–502. https://doi.org/10.1016/j.ejim.2013.05.009; PMid:23743117
Nathanson S, Ulinski T, Frémeaux-Bacchi V, Deschênes G. 2006. Secondary failure of plasma therapy in factor H deficiency. Pediatr. Nephrol. 21:1769–71. https://doi.org/10.1007/s00467-006-0237-9; PMid:16909242
Nester C, Stewart Z, Myers D et al. 2011. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin. J. Am. Soc. Nephrol. 6 (6): 1488–94. https://doi.org/10.2215/CJN.10181110; PMid:21617085 PMCid:PMC3109948
Nester CM, Thomas CP. 2012. Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated? ASH Education Program Book 1: 617–625.
Noris M, Caprioli J, Bresin E, Mossali C et al. 2010. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin. J. Am. Soc. Nephrol. 5 (10): 1844–59. https://doi.org/10.2215/CJN.02210310
PMid:20595690 PMCid:PMC2974386
Noris M, Galbusera M, Gastoldi S et al. 2014. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 124: 1715–26. https://doi.org/10.1182/blood-2014-02-558296; PMid:25037630 PMCid:PMC4162105
Novitzky N, Thomson J, Abrahams L, du Toit C et al. 2005. Thrombotic thrombocytopenic purpura in patients with retroviral infection is highly responsive to plasma infusion therapy. Br. J. Haematol. 128: 373–9. https://doi.org/10.1111/j.1365-2141.2004.05325.x; PMid:15667540
Rock GA, Shumak KH, Buskard NA et al. 1991. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N. Engl. J. Med. 325: 393–7. https://doi.org/10.1056/NEJM199108083250604; PMid:2062330
Saad AF, Roman J, Wyble A, Pacheco LD. 2016. Pregnancy-Associated Atypical Hemolytic-Uremic Syndrome. AJP reports 6 (1): 125–8. https://doi.org/10.1055/s-0036-1579539; PMid:26989566 PMCid:PMC4794438
Shrivastava M. 2011. Early diagnosis and management of postpartum hemolytic uremic syndrome with plasma exchange. Transfus. Apheresis Sci. 44: 257–262. https://doi.org/10.1016/j.transci.2011.04.004; PMid:21550309
Shukevich DL, Peredelkin DK, Grigoryev EV, Razumov AS et al. 2010. Continuous renal replacement therapy for severe obstetric sepsis. General Reanimatology 4 (2): 21–24. https://doi.org/10.15360/1813-9779-2010-2-21
Tedesco F, Pausa M, Nardon E, Introna M et al. 1997. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J. Exp. Med. 185 (9): 1619–27. https://doi.org/10.1084/jem.185.9.1619; PMid:9151899
Wong Edwin KS, Kavanagh D. 2018. Diseases of complement dysregulation – an overview. Seminars in immunopathology 40 (1): 49–64. https://doi.org/10.1007/s00281-017-0663-8; PMid:29327071 PMCid:PMC5794843
Woodward L, Johnson S, Walle JV et al. 2016. An innovative and collaborative partnership between patients with rare disease and industry-supported registries: the Global aHUS Registry. Orphanet J. Rare Dis. 11 (1): 154. https://doi.org/10.1186/s13023-016-0537-5; PMid:27871301 PMCid:PMC5117495
##submission.downloads##
Опубліковано
Номер
Розділ
Ліцензія
Авторське право (c) 2019 Здоров’я жінки
Ця робота ліцензується відповідно до Creative Commons Attribution-NonCommercial 4.0 International License.
